Published in Circulation on August 18, 2008
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
Drug-induced long QT syndrome. Pharmacol Rev (2010) 2.55
MicroRNA profiling and head and neck cancer. Comp Funct Genomics (2009) 1.68
Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol (2014) 1.65
A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet (2011) 1.48
Resolving the M-cell debate: why and how. Heart Rhythm (2011) 1.45
The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS One (2012) 1.31
Quantification of repolarization reserve to understand interpatient variability in the response to proarrhythmic drugs: a computational analysis. Heart Rhythm (2011) 1.31
Repolarization reserve: a moving target. Circulation (2008) 1.20
Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol (2011) 1.12
Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. ScientificWorldJournal (2012) 0.98
Inter-subject variability in human atrial action potential in sinus rhythm versus chronic atrial fibrillation. PLoS One (2014) 0.98
Pore mutants of HERG and KvLQT1 downregulate the reciprocal currents in stable cell lines. Am J Physiol Heart Circ Physiol (2010) 0.93
Refining repolarization reserve. Heart Rhythm (2011) 0.90
Cell-specific cardiac electrophysiology models. PLoS Comput Biol (2015) 0.90
Variability in cardiac electrophysiology: Using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigm. Prog Biophys Mol Biol (2015) 0.88
MicroRNA regulation of neuron-like differentiation of adipose tissue-derived stem cells. Differentiation (2009) 0.82
Assessment of the Spatial QRS-T Angle by Vectorcardiography: Current Data and Perspectives. Curr Cardiol Rev (2009) 0.80
The genetics of pro-arrhythmic adverse drug reactions. Br J Clin Pharmacol (2014) 0.80
A novel transgenic rabbit model with reduced repolarization reserve: long QT syndrome caused by a dominant-negative mutation of the KCNE1 gene. Br J Pharmacol (2016) 0.78
MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression: an atrial tachypacing rabbit model. PLoS One (2013) 0.78
The spatial QRS-T angle: implications in clinical practice. Curr Cardiol Rev (2013) 0.78
Genetic screening in acquired long QT syndrome? CAUTION: proceed carefully. Eur Heart J (2015) 0.77
MicroRNAs in cardiac arrhythmia: DNA sequence variation of MiR-1 and MiR-133A in long QT syndrome. Scand J Clin Lab Invest (2014) 0.77
The Electrogenic Na(+)/K(+) Pump Is a Key Determinant of Repolarization Abnormality Susceptibility in Human Ventricular Cardiomyocytes: A Population-Based Simulation Study. Front Physiol (2017) 0.76
Reduction in dynamin-2 is implicated in ischaemic cardiac arrhythmias. J Cell Mol Med (2014) 0.76
Pharmacogenetics of Potassium Channel Blockers. Card Electrophysiol Clin (2016) 0.75
Characterization of maturation of neuronal voltage-gated sodium channels SCN1A and SCN8A in rat myocardium. Mol Cell Pediatr (2015) 0.75
Delayed-rectifier potassium currents and the control of cardiac repolarization: Noble and Tsien 40 years after. J Physiol (2008) 0.75
The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med (2007) 7.59
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Retracted The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci (2007) 4.09
Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol (2008) 4.01
Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation (2010) 3.72
Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol (2012) 2.96
Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol (2007) 2.83
Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation (2012) 2.58
Retracted Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem (2008) 2.41
Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest (2011) 2.38
Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. J Am Coll Cardiol (2013) 2.38
Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol (2008) 2.37
Retracted MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem (2007) 2.14
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol (2012) 2.08
The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res (2014) 2.07
MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation (2010) 2.07
Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res (2004) 2.06
Sinus node dysfunction and hyperpolarization-activated (HCN) channel subunit remodeling in a canine heart failure model. Cardiovasc Res (2005) 2.02
Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res (2007) 2.02
Atrial fibrillation pathophysiology: implications for management. Circulation (2011) 2.01
Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res (2002) 2.00
Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. Am J Physiol Heart Circ Physiol (2002) 2.00
miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J (2011) 1.98
Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J (2005) 1.96
Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation (2003) 1.86
Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol (2007) 1.85
Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation (2012) 1.81
Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev (2006) 1.80
Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res (2010) 1.74
Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm (2007) 1.71
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J (2005) 1.71
Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J Am Coll Cardiol (2013) 1.68
Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res (2014) 1.68
Pulmonary vein reentry--properties and size matter: insights from a computational analysis. Heart Rhythm (2007) 1.68
Improved outcome following restoration of sinus rhythm prior to catheter ablation of persistent atrial fibrillation: a comparative multicenter study. Heart Rhythm (2012) 1.67
Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation (2005) 1.67
National survey on critical values notification of 599 institutions in China. Clin Chem Lab Med (2013) 1.66
Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. Am J Physiol Heart Circ Physiol (2005) 1.65
New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet (2010) 1.65
Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation (2004) 1.64
Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation (2008) 1.61
Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. Heart Rhythm (2012) 1.59
Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm (2010) 1.59
Retracted Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol (2007) 1.59
Ca(2+)-related signaling and protein phosphorylation abnormalities play central roles in a new experimental model of electrical storm. Circulation (2011) 1.58
A proposal for new clinical concepts in the management of atrial fibrillation. Am Heart J (2012) 1.57
In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovasc Res (2004) 1.55
Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol (2010) 1.55
Atrial fibrillation-associated minK38G/S polymorphism modulates delayed rectifier current and membrane localization. Cardiovasc Res (2005) 1.54
Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circ Res (2002) 1.54
Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm (2009) 1.54
Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling. Heart Rhythm (2009) 1.53
Molecular basis of funny current (If) in normal and failing human heart. J Mol Cell Cardiol (2008) 1.53
Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog. Circulation (2013) 1.51
Atrial fibrillation-associated remodeling does not promote atrial thrombus formation in canine models. Circ Arrhythm Electrophysiol (2012) 1.50
MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest (2013) 1.49
Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol (2010) 1.49
Involvement of lipid rafts and caveolae in cardiac ion channel function. Cardiovasc Res (2006) 1.48
Region-specific gene expression profiles in the left atria of patients with valvular atrial fibrillation. Heart Rhythm (2012) 1.47
Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res (2014) 1.47
Differential effectiveness of pharmacological strategies to reveal dormant pulmonary vein conduction: a clinical-experimental correlation. Heart Rhythm (2011) 1.45
Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties. J Physiol (2003) 1.45
Role of T-type calcium channel subunits in post-myocardial infarction remodelling probed with genetically engineered mice. Cardiovasc Res (2011) 1.44
Transmural expression of transient outward potassium current subunits in normal and failing canine and human hearts. J Physiol (2004) 1.44
Cellular properties of C-terminal KCNH2 long QT syndrome mutations: description and divergence from clinical phenotypes. Heart Rhythm (2008) 1.43
HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. Cancer Res (2002) 1.43
Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov (2012) 1.42
Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation (2004) 1.41
Comparison of ion-channel subunit expression in canine cardiac Purkinje fibers and ventricular muscle. Circ Res (2002) 1.41
Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. J Mol Cell Cardiol (2010) 1.37
A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J Physiol (2002) 1.35
Newborn screening in China: phenylketonuria, congenital hypothyroidism and expanded screening. Ann Acad Med Singapore (2008) 1.33
MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation (2013) 1.33
Novel approaches for pharmacological management of atrial fibrillation. Drugs (2009) 1.32
Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation (2002) 1.31